Among tumor stem cell regulatory agents, tarextumab initially showed encouraging results in a Phase I study; however, an interim analysis of a Phase II study showed a strong trend to a lack of benefit, and the trial was discontinued due to futility (ClinicalTrials.gov Identifier: NCT01647828 ;[ 15 ]).
← all excerpts
The personalized medicine for pancreatic ductal adenocarcinoma patients: The oncologist perspective.
1
—
—